$DTIL News

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences Doses First Patient In The Phase 1/2 Function-DMD Clinical Trial Evaluating PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy

iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium

Precision BioSciences: Promising HBV Editing Evidence

Precision BioSciences (NASDAQ:DTIL) Passes Minervini Trend Template and High-Growth Momentum Screen

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

Precision BioSciences Promotes Alex Kelly To COO And Naresh Tanna To CFO, Effective August 1, 2026

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial Results - Slideshow

Why Is Precision BioSciences Stock Gaining Wednesday?

Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B Study